atorvastatin has been researched along with Cirrhosis, Liver in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 9 (40.91) | 2.80 |
| Authors | Studies |
|---|---|
| Mukhamejanova, Z; Pang, J; Tong, Y; Wen, T; Xiang, Q; Xu, F; Zhu, W | 1 |
| Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z | 1 |
| Ghazi-Khansari, M; Jazaeri, F; Mehreen, S; Niaz, Q; Tavangar, SM | 1 |
| Caspers, MPM; Giera, M; Inia, JA; Jukema, JW; Menke, AL; Morrison, MC; Pieterman, EJ; Princen, HMG; Stokman, G; van den Hoek, AM; Verschuren, L | 1 |
| Andersen, ML; Bendtsen, F; Gantzel, RH; Gao, Q; Grønbæk, H; Hobolth, L; Kimer, N; Kronborg, TM; Moritz, T; Møller, S; Schierwagen, R; Teisner, AS; Trebicka, J; Trošt, K | 1 |
| Goudarzi, F; Hashemnia, M; Mohammadalipour, A; Ravan, AP | 1 |
| Bendtsen, F; Deshmukh, AS; Fred, RG; Grønbæk, H; Hansen, T; Kimer, N; Mann, M | 1 |
| Moradi, A; Nozari, E; Samadi, M | 1 |
| Abraldes, JG; Al-Karaghouli, M; Cabrera Garcia, L; Kalainy, S; Sung, S | 1 |
| Augustin, S; Barberá, A; Bravo, M; Estrella, F; Genescà, J; Gil, M; Hide, D; Martell, M; Raurell, I; Salcedo, MT | 1 |
| Gao, H; Hu, Y; Li, X; Tian, R; Wang, Y; Williams, BR; Xu, P; Yan, F; Ying, L; Zhao, Y | 1 |
| Ahammed, SM; Bishnu, S; Chatterjee, S; Chowdhury, A; Das, K; Dhali, GK; Hembram, J; Sarkar, A | 1 |
| Baiges, A; Bosch, J; Hernández-Gea, V | 1 |
| Abdel-Halim, M; Asimakopoulou, A; Hassan, R; Mansour, S; Safy, SE; Tammam, SN; Weiskirchen, R | 1 |
| Eshraghian, A; Kamyab, AA | 1 |
| Bonilla, H; Butt, AA; Chung, RT; Simon, TG; Yan, P | 1 |
| Dushkin, MI; Komarova, NI; Kuznetsova, IS; Schwartz, YSh; Vorontsova, EV | 1 |
| Dienes, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Lammert, F; Odenthal, M; Reichen, J; Sauerbruch, T; Shir, K; Trebicka, J; Vogt, A | 1 |
| Fürst, DO; Granzow, M; Huss, S; Klein, S; Klösel, J; Körner, C; Lammert, F; Mazar, IG; Nattermann, J; Pieper-Fürst, U; Sauerbruch, T; Schierwagen, R; Trebicka, J; van den Ven, PF; Weber, S | 1 |
| Aeed, H; Bruck, R; Gavish, D; Sharvit, E; Shirin, H | 1 |
| Biecker, E; Heller, J; Hennenberg, M; Laleman, W; Nevens, F; Sauerbruch, T; Schepke, M; Shelest, N; Trebicka, J | 1 |
| Méndez-Sánchez, N; Uribe, M; Zamora-Valdés, D | 1 |
2 review(s) available for atorvastatin and Cirrhosis, Liver
| Article | Year |
|---|---|
A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Pravastatin; Simvastatin | 2021 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Incidence; Liver; Liver Cirrhosis; Nitric Oxide Synthase Type III; Portal Pressure; Propanolamines; Propranolol; Simvastatin; Splanchnic Circulation | 2018 |
3 trial(s) available for atorvastatin and Cirrhosis, Liver
| Article | Year |
|---|---|
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial.
Topics: Anti-Inflammatory Agents; Atorvastatin; End Stage Liver Disease; Humans; Hypertension, Portal; Liver Cirrhosis; Severity of Illness Index | 2023 |
Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial.
Topics: Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome | 2020 |
Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atorvastatin; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypertension, Portal; India; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Proof of Concept Study; Propranolol; Prospective Studies; Single-Blind Method; Time Factors; Treatment Outcome | 2018 |
17 other study(ies) available for atorvastatin and Cirrhosis, Liver
| Article | Year |
|---|---|
Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR alpha; Proteomics; Pyrans; Signal Transduction | 2022 |
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Cirrhosis; Medicare; Metformin; Paracentesis; Rifaximin; Risk Factors; United States | 2022 |
Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cholesterol; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Liver; Liver Cirrhosis; Male; Malondialdehyde; Natriuretic Peptides; NF-E2-Related Factor 2; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Tumor Necrosis Factor-alpha | 2022 |
Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation.
Topics: Animals; Apolipoproteins E; Atorvastatin; Cholesterol; Diet; Inflammasomes; Inflammation; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease | 2023 |
Increasing the effectiveness of tyrosine kinase inhibitor (TKI) in combination with a statin in reducing liver fibrosis.
Topics: Animals; Atorvastatin; Carbon Tetrachloride; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Hepatic Stellate Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Wistar; Treatment Outcome | 2019 |
Effect of Atorvastatin, Curcumin, and Quercetin on miR-21 and miR-122 and their correlation with TGFβ1 expression in experimental liver fibrosis.
Topics: Animals; Atorvastatin; Curcumin; Gene Expression; Liver; Liver Cirrhosis; Male; MicroRNAs; Quercetin; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Transforming Growth Factor beta1 | 2020 |
Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH.
Topics: Alanine Transaminase; Animals; Atorvastatin; Biomarkers; Collagen; Disease Models, Animal; Drug Synergism; Endothelial Cells; Endothelin-1; Enzyme Activation; Hemodynamics; Hepatic Stellate Cells; Insulin Resistance; Liver; Liver Cirrhosis; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyridazines; Weight Gain | 2021 |
(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease.
Topics: Animals; Atorvastatin; Catechin; Disease Models, Animal; Down-Regulation; Fibrillar Collagens; Gene Expression; Humans; Liver Cirrhosis; Male; Mice, Inbred C57BL; Multigene Family; Non-alcoholic Fatty Liver Disease | 2017 |
Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.
Topics: Actins; Animals; Atorvastatin; Azepines; Carbon Tetrachloride; Chitosan; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Synergism; HEK293 Cells; Hepatic Stellate Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Mice; Nanoparticles; Nuclear Proteins; Transcription Factors; Treatment Outcome; Triazoles; Vitamin A | 2019 |
Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Liver Cirrhosis; Pyrroles; Rhabdomyolysis | 2013 |
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fibrosis; Fluvastatin; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged | 2016 |
Cholesterol-induced stimulation of postinflammatory liver fibrosis.
Topics: Animals; Atorvastatin; Calcitriol; Cholesterol Esters; Cholesterol, Dietary; Collagen; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Pyrroles; Transforming Growth Factor beta1; Triglycerides; Zymosan | 2008 |
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells.
Topics: Animals; Atorvastatin; Bile Ducts; Cell Proliferation; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Liver Cirrhosis; Male; Pyrroles; Rats; Rats, Sprague-Dawley | 2010 |
Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats.
Topics: Actins; Aging; Animals; Apoptosis; Atorvastatin; beta-Galactosidase; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Desmin; Dose-Response Relationship, Drug; Flow Cytometry; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Myofibroblasts; Pyrroles; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1 | 2012 |
Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Fluorobenzenes; Hepatic Stellate Cells; Heptanoic Acids; Hypertension, Portal; In Vitro Techniques; Incidence; Injections; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Oxidative Stress; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Thioacetamide | 2013 |
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Topics: Animals; Atorvastatin; Blood Pressure; Enzyme Activation; Heptanoic Acids; Hydroxyproline; Intracellular Signaling Peptides and Proteins; Liver Cirrhosis; Male; Nitric Oxide Synthase Type III; Portal System; Protein Serine-Threonine Kinases; Pyrroles; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; rhoA GTP-Binding Protein | 2007 |
Atorvastatin and portal pressure.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Liver Cirrhosis; Pyrroles; Rats | 2007 |